Status:
COMPLETED
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
Lead Sponsor:
Corcept Therapeutics
Conditions:
Antipsychotic-induced Weight Gain
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This study will investigate if there is any difference in the amount of weight gained by participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy test medicine whi...
Eligibility Criteria
Inclusion
- Body mass index 18.0 to 25.0 kg/m\^2, inclusive
- Stable body weight as indicated by assessment at screening and pre-dose
- Able to swallow the size and number of tablets required
- Provide written informed consent and agree to adhere to study restrictions and contraception requirements.
Exclusion
- Have received any investigational medicine in a clinical research study within the previous 3 months, or CORT118335 at any time
- Employee, or immediate family member of a study site or Sponsor employee
- Have a pregnant partner
- History of abuse of any drug or alcohol, or regularly consume more than 21 units alcohol/week
- Smokers or users of e-cigarettes and nicotine replacement products within the last 6 months
- Clinically significant abnormal results of clinical laboratory safety tests, electrocardiogram, or measurement of heart rate and blood pressure
- History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, or gastrointestinal disease, neurological or psychiatric disorder
- History of jaundice or gallstones or had a cholecystectomy
- Family history or known risk for narrow angle glaucoma
- Consumed liquorice or other glycyrrhetic acid derivatives regularly in the past 6 months
- Any condition that could be aggravated by glucocorticoid and/or mineralocorticoid antagonism (e.g., asthma, any chronic inflammatory condition, postural hypotension/orthostatic symptoms)
- Presence or history of clinically significant allergy
- Donation or loss of greater than 400 mL of blood within the previous 3 months
- Are taking, or have taken, any prescribed or over-the-counter drug within 14 days other than paracetamol or standard dose multivitamins. Longer restrictions apply for some medicines.
- Lactose intolerance.
- NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2020
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT03877562
Start Date
April 1 2019
End Date
March 25 2020
Last Update
April 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Sciences
Ruddington, Nottingham, United Kingdom, NG11 6JS